Interviews

Noopur Raje, MD, discusses the current treatment options for patients diagnosed with multiple myeloma. At this time, a number of FDA-approved drugs and different combinations are available.

Floor J. Backes, MD, discusses the side effects associated with the combination lenvatinib plus paclitaxel in patients with recurrent endometrial and platinum-resistant epithelial ovarian cancer.

Myung-Ju Ahn, MD, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, discusses the findings from the AURA LM study, which compared an 80 mg dose of osimertinib with a 160 mg dose in patients with <em>EGFR</em>-positive advanced non&ndash;small cell lung cancer with leptomeningeal metastases.

William G. Wierda, MD, PhD, discusses the take home message from the phase III MURANO trial that identified venetoclax plus rituximab as a new treatment option for patients with relapsed/refractory chronic lymphocytic leukemia.

Andre Goy, MD, discusses the role of rituximab and bendamustine plus cytarabine as a treatment for patients with mantle cell lymphoma.

Tony Mok, MD, discusses the next steps for pembrolizumab (Keytruda) as a treatment option for patients with non-small cell lung cancer after the phase III KEYNOTE-042 trial.

Alexander E. Perl, MD, discusses the latest advancements in the treatment landscape for patients with acute myeloid leukemia. These advances are driven by 2 factors: a better understanding of the biology of the disease and improving therapeutics to meet that understanding.

Ryan J. Sullivan, MD, discusses the role of checkpoint inhibitors in the treatment landscape for patients with melanoma.

Elias Jabbour, MD, discusses the latest advancements in the treatment landscape for acute lymphocytic leukemia that are moving the paradigm away from chemotherapy.

Thomas W. Flaig, MD, discusses the most dramatic change in the treatment landscape for patients with advanced bladder cancer. Over the last several years, 5 checkpoint inhibitors have been approved in this space.

John H. Ward, MD, discusses the role of 21-gene assays in selecting patients with breast cancer for adjuvant chemotherapy treatment.

Carla Casulo, MD, discusses the challenges surrounding the treatment of patients with relapsed/refractory follicular lymphoma.

Ahmed Omar Kaseb, MD, associate professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, says 2 major challenges in hepatocellular carcinoma are the lack of effective treatments and the co-existing underlying chronic liver disease.

David S. Hong, MD, discusses the potential for other TRK inhibitors in the treatment landscape for patients with thyroid cancer after the approval of larotrectinib.

Andre Goy, MD, discusses a few combinations that are being investigated for the treatment of patients with relapsed/refractory mantle cell lymphoma.

Silvia C. Formenti, MD, discusses the advantages of radiation therapy in patients with lung cancer compared to other modalities.

Srdan Verstovsek, MD, PhD, discusses the use of ruxolitinib as a second-line treatment of patients with polycythemia vera.

Suresh S. Ramalingam, MD, professor of hematology and medical oncology at the Emory University School of Medicine, discusses the challenge of brain metastases in <em>EGFR</em>-mutated lung cancer and the data surrounding osimertinib (Tagrisso) in this patient population.

During the 2019 AACR Annual Meeting, Vassiliki Papadimitrakopoulou, MD,&nbsp;professor of medicine, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the NILE study&nbsp;and what they mean for the clinical utility of liquid biopsies for the detection of biomarkers in NSCLC.

William G. Wierda, MD, PhD, discusses data surrounding the use of ibrutinib in combination with venetoclax as a treatment option for patients with newly diagnosed CLL as well as relapsed CLL.

Alexander E. Perl, MD, discusses results from the phase III ADMIRAL trial, which demonstrated a significant improvement in overall survival in patients with <em>FLT3</em>-mutated acute myeloid leukemia treated with the FLT3 inhibitor gilteritinib.

Nathan H. Fowler, MD, discusses the latest addition to the treatment landscape for marginal zone lymphoma.

Pashtoon M. Kasi, MD, MBBS, MS, discusses how genetic testing is underutilized in colorectal cancer, despite its ability to guide treatment dosing and adjustment based on the mutations or variations within a patient.

William J. Gradishar, MD, discusses the NCCN guidelines in regard to selecting molecular assays for patients with breast cancer. Currently, there are 3 available assays that clinicians can order: 21-gene, 50-gene, and 70-gene assays.

Frederick L. Locke, MD, discusses how chimeric antigen receptor (CAR) T-cell therapies have evolved over the last 30 years of research in the field of hematologic malignancies.

Saad Z. Usmani, MD, FACP, chief of&nbsp;Plasma&nbsp;Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses how to manage early relapse in multiple myeloma.

Peter Grivas, MD, PhD, discusses the next steps necessary for the treatment landscape of advanced urothelial cancer to evolve.

<p>David S. Hong, MD, discusses the results from the phase II innovaTV 201 trial looking at the antibody-drug conjugate tisotumab vedotin in patients with metastatic&nbsp; or recurrent cervical cancer.</p>

Kevin Staveley-O&rsquo;Carroll, MD, PhD, discusses one of the challenges in treating patients with hepatocellular carcinoma and shares what he thinks are the next steps in overcoming this challenge.

Alexander E. Drilon, MD, discusses the next steps for LOXO-292 in 2 subsets of patients: those with RET fusion-positive cancers and <em>RET</em>-mutant medullary thyroid cancers.